To determine the true impact of ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL) within a population-based setting rather than a clinical trial setting, Lina van der Straten, PhD, of the Albert Schweitzer Hospital, Dordrect, Netherlands, outlines her collaboration with the Netherlands Cancer Registry, which allowed her to analyze patient survival over a prolonged period of time and draw some promising conclusions. Dr van der Straten presented these results at the 23rd Congress of the European Hematology Association (EHA) 2018 in Stockholm, Sweden.
Ibrutinib for CLL within a population-based setting: a promising outlook
